Picking a cancer hospital in Bangalore gets easier when it is split into three questions. What treatment can the hospital really give? How much experience do its doctors have with your kind of cancer? How will the bill be handled? Families looking for the best cancer hospital often find that no single name fits everyone, and rankings or word of mouth rarely answer these questions. This blog explains what to check, what to ask and how to compare.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in Bengaluru at MACS Clinic, many patients pick a hospital on reputation or distance before the diagnosis and stage are fully known. It is more useful to confirm the cancer type and the treatment plan first, and then see which hospital can carry out that plan from start to finish. A second opinion at this stage is common and sensible.

• Treatment under one roof. Surgery, chemotherapy, radiotherapy, imaging and pathology should all be available, so care isn’t split across places. The full list of cancer treatments shows how wide surgical oncology alone can be.
• A tumour board. Find out if surgeons, medical and radiation oncologists, a radiologist and a pathologist look at each case together. Or does one doctor decide alone?
• Accreditation. NABH is the national mark for hospital quality and safety. Ask which exact facility holds it.
• Experience with your cancer. Ask how often the team treats your type of cancer. The team of oncologists page shows how a surgical oncology team is organised.
• Modern surgical options. Some tumours can be removed through small cuts with robotic cancer surgery or laparoscopic cancer surgery. That often means less pain and an earlier discharge, though not every case suits it.
• Back-up care. Intensive care, a blood bank, nutrition advice and rehab all count, especially for big operations.

• A written estimate. Get it in writing, and ask what is left out: scans, drugs, ICU days, follow-up visits.
• Cashless tie-ups. Check that the hospital is in your insurer’s network, and ask who sends the pre-authorisation request.
• Sub-limits. Some policies cap certain procedures.
• Government schemes. Families eligible for schemes like Ayushman Bharat–Arogya Karnataka should ask whether the hospital takes that route for their particular treatment.
• No pressure. A good hospital gives you time to decide, puts costs in writing and doesn’t promise a certain outcome.

Breast cancer surgery in India typically costs ₹1 lakh to ₹5 lakh. Lumpectomy usually costs less than mastectomy. Reconstruction, robotic surgery and lymph node removal can increase costs. The final bill depends on the hospital, procedure and length of stay.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in Bengaluru  at MACS Clinic, “Cost is the first thing most families ask me about, and honestly that’s fine. What I don’t do is choose an operation because it’s cheaper. We decide what’s right for the tumour first, then sit down and talk about the numbers,” 

Rates differ from one hospital to the next, so read these as ballpark figures from private specialist centres.

• Lumpectomy: ₹75,000 to ₹2,00,000. The operation is small, but radiation comes after it and that is billed on its own.
• Mastectomy: ₹1,00,000 to ₹3,50,000. It is a longer surgery with more days in hospital. Weighing the two? Our post on lumpectomy vs mastectomy cost goes through it.
• Sentinel node biopsy: about ₹40,000 to ₹80,000 extra, done during the same admission.
• Reconstruction: an implant adds ₹1,00,000 to ₹2,50,000. A flap adds ₹2,00,000 to ₹5,00,000.
• Robotic surgery: roughly ₹50,000 to ₹1,50,000 more at hospitals that offer robotic cancer surgery. Most of that is the instruments and robot time.

Pick up any hospital estimate and you’ll find the same handful of lines: surgeon’s fee, OT charges, room rent, anaesthesia, and the pathology and scans around the surgery. An implant or flap is extra.

What catches people off guard is what’s left out. Chemo, radiation, targeted injections and the years of hormone tablets are not in that number. For some patients the second bill is as big as the first, sometimes bigger. Our post on breast cancer surgery cost in Bangalore shows how the whole treatment adds up.

Often it can. When the cancer is small and sits in one spot, the surgeon can take out just the tumour and keep the rest of the breast, so a mastectomy never comes into it. The catch is that the answer isn’t the same for everyone. Tumour size, position, the number of areas involved and whether radiation is safe all push the decision one way or the other. This blog looks at that “instead of” question directly: when you can avoid a mastectomy, when you can’t, and how the choice gets made.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in Bengaluru at MACS Clinic, the first thing most women ask is whether they can keep their breast. The honest answer comes from the reports, not from a general rule, and two women with the same cancer can end up with different plans because of tumour position, breast size and their own wishes. It helps to go through the options before a surgery date is fixed.

In short, conservation is considered when the cancer can be removed completely and the breast can still be treated safely afterwards. The full checklist is in our post on what breast-conserving surgery involves and who qualifies, so here is the short version.

• A small, single tumour. One area of cancer that can come out with clear margins and still leave a breast worth keeping.
• Early stage. Stage 0, stage 1 and many stage 2 cancers are the usual candidates.
• A tumour that shrinks first. If the cancer is too big at diagnosis, chemotherapy before surgery can sometimes bring it within range.
• Reshaping at the same operation. The breast cancer treatment page explains how oncoplastic techniques widen the choice.
• No loss of survival for the right patient. The lumpectomy vs mastectomy guide compares the two operations side by side.

• A tumour too big for the breast. Taking it out would leave too little tissue behind.
• Cancer in more than one area. Separate tumours in different parts of the breast usually mean mastectomy, though a few centres consider conservation for selected cases.
• Radiation can’t be given. Earlier chest radiation, early pregnancy or certain connective tissue conditions can rule conservation out.
• Inflammatory breast cancer. It is generally treated with mastectomy after chemotherapy.
• Margins that won’t clear. If cancer cells are still at the edge after a second look, removing the whole breast is the safer route.
• High genetic risk. With a confirmed BRCA mutation, many women choose mastectomy. The post on whether breast cancer is hereditary explains who needs testing.

Mastectomy also isn’t one single operation. Our post on partial and total mastectomy explains the difference.

A Whipple procedure (pancreaticoduodenectomy) is a major abdominal operation, and recovery takes several weeks to a few months. A week to ten days in hospital is typical, followed by a slower recovery at home as appetite, weight and strength return. What follows is the Whipple surgery recovery timeline, from the hospital stay to the first follow-up visits.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in Bengaluru at MACS Clinic, patients and families often expect one date by which everything is back to normal. “There is no such date with a Whipple. The wound heals first, then the energy, then the appetite and weight. Each has its own pace, and that is quite normal. What helps is walking daily, eating small meals often and keeping every follow-up appointment.”

Day one. The first day is spent in recovery or intensive care, under close watch. A drip, a catheter and a drain or two will be attached. Some patients also have a thin tube running through the nose into the stomach.

Eating again. Sips of water start soon after surgery. Then comes tea or juice, and by about the third day, soft food. Nothing tastes quite right at first and the appetite lags behind, so tiny portions are all most patients manage.

Getting moving. Patients sit in a chair on day one and walk a little further each day. Where the operation is done by robotic cancer surgery, the wounds are smaller and moving about is often easier. The internal reconstruction, and the healing it needs, stay the same.

Going home. Most patients leave hospital after a week to ten days. A few stay longer. A leak from one of the new joins, or a stomach that is slow to start working, can add a week or more.

Weeks one and two. Most people are surprised by how weak they feel. A ten-minute walk, a rest, then another walk later in the day suits most patients better than one long outing. Meals are a chore at first. Food tastes dull and a full plate is off-putting, so five or six small servings through the day tend to go down better. By the second week, most notice a bit more energy.

Weeks three to six. Small things start to feel possible again, like a trip to the shop or helping in the kitchen. Ordinary activities come back at around four to six weeks for most patients. Some take longer, and that’s all right. Weight often drops in this stretch, and a dietitian’s advice helps.

Lifting and driving. For two to three months nothing heavy should be lifted, not even a full bag of vegetables. As for driving, the patient should be able to wear the seat belt without wincing and press the brake hard if needed.

Digestion and blood sugar. Many patients go home on enzyme capsules, taken with every meal and snack. With part of the pancreas gone, the body makes fewer digestive juices, and the capsules fill the gap. Pale, greasy stools that float, or loose ones, usually mean the dose needs a tweak. Sugar needs watching as well. The pancreas is also where insulin is made, and with less of it, blood sugar can run high. A patient who is thirsty all the time, needing the toilet far more often or losing weight for no clear reason should tell the team.

Months two to three and beyond. Energy and appetite keep creeping back through the second and third months. Tiredness can hang around longer than anyone expects. The first review visits come at about four to eight weeks after the operation. If the Whipple was done for cancer, chemotherapy may be planned once the body has recovered enough for it.

Can rectal cancer be treated without undergoing surgery? With advances in immunotherapy, some patients can now be treated without surgery. Although surgery is still an important part of the treatment of rectal cancer, some patients respond clinically to immunotherapy and could avoid immediate surgery.

Immunotherapy for rectal cancer is a method in which the body’s immune system recognizes and attacks cancer cells. There have been promising results from clinical studies of patients who had mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) rectal cancer.

According to Dr. Sandeep Nayak, a well-known surgical oncologist in India, “The possibility of rectum preservation is a major advancement in cancer care. But treatment strategies need to consider tumor biology, proper staging, response assessment, and long-term surveillance rather than focusing only on avoiding surgery.”

With a focus on personalized rectal cancer care, Dr. Nayak shares valuable insights into emerging treatment approaches and surgical strategies. His experience in colorectal oncology helps him educate patients about immunotherapy, organ preservation, and more.

This blog explains who may benefit from immunotherapy, how treatment works, and when surgery may still be necessary.

What Is Immunotherapy for Rectal Cancer?

Immunotherapy is a cancer treatment that strengthens the immune system’s ability to identify and eliminate cancerous cells. Unlike chemotherapy, which targets rapidly dividing cells, immunotherapy can help immune cells overcome mechanisms cancer cells use to escape detection.

In rectal cancer, drugs such as dostarlimab and pembrolizumab target the PD-1 pathway, helping T-cells recognize cancerous cells.

Immunotherapy has shown particularly promising results in rectal tumors with dMMR/MSI-H characteristics. These tumors contain genetic changes that may make them more recognizable to the immune system.

However, not every rectal tumor responds equally. Molecular testing is essential before selecting this treatment.

Why do certain rectal tumors respond better to immunotherapy? Let’s understand how tumor genetics influence treatment decisions.

Can Immunotherapy Help Some Rectal Cancer Patients Avoid Surgery?

Yes. Some selected patients with locally advanced dMMR rectal cancer can achieve a complete clinical response after immunotherapy treatment, allowing doctors to consider a non-operative management strategy.

In a study published in the New England Journal of Medicine in 2025, a complete clinical response was observed in all 49 patients with locally advanced dMMR rectal cancer who had undergone dostarlimab treatment. These results are promising, but further research is needed for better outcomes.

A complete clinical response means no signs of cancer on examination or imaging. It does not mean that every cancer cell has been eradicated.

For those patients with a non-operative approach, there will be regular exams, MRIs, and endoscopy.

Does a complete response mean surgery is permanently unnecessary? Let’s examine why careful monitoring remains essential.

Which Rectal Cancer Patients May Benefit Most From Immunotherapy?

Patients who have rectal cancer with dMMR/MSI-H are the most established candidates for immune checkpoint inhibitor treatment.

Eligibility is based on various criteria:

Testing for mismatch repair proteins like MLH1, MSH2, MSH6, and PMS2 is an effective way to identify eligible tumors.

Patients interested in rectal cancer care in Bangalore must undergo complete staging and molecular analysis before opting for immunotherapy.

Dr. Sandeep Nayak, a well-known oncologist in Bangalore, says, “A patient’s suitability for immunotherapy depends on more than the cancer diagnosis. Molecular findings, tumor extent, and the ability to complete long-term follow-up are equally important.”

How Is Immunotherapy Given for Rectal Cancer?

It is mostly administered through intravenous infusion in a specialized cancer treatment facility.

The procedure usually involves:

In the landmark dostarlimab study, treatment took about six months. There might be different regimens for other schedules.

Patients seeking cancer treatment in Bangalore should understand that immunotherapy requires experienced multidisciplinary coordination.

What Are the Risks of Choosing a Non-Surgical Approach?

Avoiding surgery could help preserve normal bowel function and reduce the possibility of a permanent stoma. However, non-operative management also carries risks.

These include:

• Residual cancer: Even though scans may show no signs of cancer, there could be microscopic disease left behind.
• Local recurrence: The cancer can recur locally in the rectum.
• Delayed surgery: Some patients may need to undergo surgery eventually if their cancer persists or recurs.
• Follow-ups: Scans and tests such as MRI scans and endoscopy need to be done regularly.
• Immunotherapy side effects: There can be inflammation in different organs, including the bowel, lungs, liver, and thyroid.

Immune-related problems can sometimes become very severe and could be potentially dangerous for the patient. An expert in the field should explain this to the patient.

Is avoiding surgery always the safest choice? Let’s understand why treatment must balance organ preservation with cancer control.

Does Immunotherapy Replace Surgery for Every Rectal Cancer Patient?

No. Not all patients with rectal cancer can have immunotherapy as a substitute for surgery.

Most rectal cancers are mismatch repair proficient (pMMR) or microsatellite stable (MSS). Such tumors tend to be less responsive to checkpoint inhibitor monotherapy.

For such patients, treatment could include chemotherapy, radiotherapy, surgery, or a combination of these.

It might also be the case that surgery is required if the patient’s immunotherapy was not fully effective, if the disease progressed, or if complications develop.

A skilled surgical oncologist in India can help with this decision.

Conclusion

Immunotherapy for rectal cancer is an important advancement in carefully selected patients with dMMR or MSI-H tumors. Some could attain complete clinical response and pursue organ preservation via close monitoring.

But not all patients qualify based on their specific molecular features, clinical stage, response to therapy, and clinical assessment. Surgery remains essential for many patients.

Dr. Sandeep Nayak stresses the importance of customized treatment, where the organ’s function should not affect cancer management.

References

• https://www.cancercenter.com/cancer-types/colorectal-cancer/treatments/immunotherapy
• https://www.cancerresearch.org/immunotherapy-by-cancer-type/colorectal-cancer

Disclaimer: The information shared in this content is for educational purposes and not for promotional use.